BCRX Stock Analysis: BioCryst Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 2.577m USD | 12M Return: 10.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 56.2M
Qual. Beats: 0
Rev. Trend: 96.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioCryst Pharmaceuticals is a U.S. biotechnology company founded in 1986 and headquartered in Durham, North Carolina, that develops and commercializes therapies for hereditary angioedema (HAE) and other rare diseases. Its marketed products include RAPIVAB (peramivir), an intravenous antiviral for acute uncomplicated influenza sold under multiple brand names internationally, and ORLADEYO, an oral prophylactic therapy for HAE.
The companys clinical pipeline spans several rare and serious conditions, led by Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE currently in Phase 3 development. Earlier-stage programs include BCX17725 for Netherton syndrome, Avoralstat for diabetic macular edema, and STAR-0310 for atopic dermatitis. BioCryst maintains commercialization and research partnerships with Torii Pharmaceutical, Shionogi, and Green Cross Corporation in Japan, U.S. government agencies such as BARDA and NIAID, and academic institutions including the University of Alabama at Birmingham and Albert Einstein College of Medicine.
As a rare disease-focused biotech, BioCryst operates within a sector where companies typically pursue orphan drug designations for therapies addressing small patient populations with limited treatment alternatives, and frequently rely on partnerships with larger pharmaceutical firms for international commercialization. The company has traded on NASDAQ since its 1994 IPO and is classified within the GICS Biotechnology sub-industry.
- ORLADEYO HAE revenue growth accelerates quarterly results
- Navenibart Phase 3 data could disrupt hereditary angioedema market
- Cash burn and profitability timeline remain key investor concerns
| Net Income: -458.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.63 > 0.02 and ΔFCF/TA 68.84 > 1.0 |
| NWC/Revenue: 20.12% < 20% (prev 53.65%; Δ -33.53% < -1%) |
| CFO/TA 0.64 > 3% & CFO 296.8m > Net Income -458.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (242.3m) vs 12m ago 12.54% < -2% |
| Gross Margin: 18.89% > 18% (prev 96.90%; Δ -78.00% > 0.5%) |
| Asset Turnover: 187.4% > 50% (prev 104.9%; Δ 82.55% > 0%) |
| Interest Coverage Ratio: -5.04 > 6 (EBIT TTM -379.0m / Interest Expense TTM 75.2m) |
| A: 0.38 (Total Current Assets 373.6m - Total Current Liabilities 195.4m) / Total Assets 465.1m |
| B: -4.79 (Retained Earnings -2.23b / Total Assets 465.1m) |
| C: -0.80 (EBIT TTM -379.0m / Avg Total Assets 472.5m) |
| D: -0.54 (Book Value of Equity -553.8m / Total Liabilities 1.02b) |
| Altman-Z'' = -19.06 = D |
| DSRI: 0.67 (Receivables 109.3m/93.4m, Revenue 885.7m/503.5m) |
| GMI: 5.13 (GM 96.90% / 18.89%) |
| AQI: 1.40 (AQ_t 0.15 / AQ_t-1 0.11) |
| SGI: 1.76 (Revenue 885.7m / 503.5m) |
| TATA: -1.62 (NI -458.0m - CFO 296.8m) / TA 465.1m) |
| Beneish M = 1.05 (Cap -4..+1) = D |
As of July 14, 2026, the stock is trading at USD 9.91 with a total of 3,097,485 shares traded. Over the past week, the price has changed by -2.56%, over one month by +9.38%, over three months by +5.31% and over the past year by +10.60%.
Current recommended Stop Loss: 9.20 (which is 7.2% or 1.3 ATR below the current price).
BioCryst Pharmaceuticals has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy BCRX.
- StrongBuy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.8 | 120% |
P/E Forward = 86.9565
P/S = 2.9097
P/B = 56.5858
P/EG = 9.3878
Revenue TTM = 885.7m USD
EBIT TTM = -379.0m USD
EBITDA TTM = -373.2m USD
Long Term Debt = 802.4m USD (from longTermDebt, last quarter)
Short Term Debt = 43.4m USD (from shortTermDebt, last quarter)
Debt = 873.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.4m
Net Debt = 634.2m USD (calculated: Debt 873.5m - CCE 239.3m)
Enterprise Value = 3.21b USD (2.58b + Debt 873.5m - CCE 239.3m)
Interest Coverage Ratio = -5.04 (Ebit TTM -379.0m / Interest Expense TTM 75.2m)
EV/FCF = 10.92x (Enterprise Value 3.21b / FCF TTM 294.1m)
FCF Yield = 9.16% (FCF TTM 294.1m / Enterprise Value 3.21b)
FCF Margin = 33.20% (FCF TTM 294.1m / Revenue TTM 885.7m)
Net Margin = -51.71% (Net Income TTM -458.0m / Revenue TTM 885.7m)
Gross Margin = 18.89% ((Revenue TTM 885.7m - Cost of Revenue TTM 718.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 6.91 (Enterprise Value 3.21b / Total Assets 465.1m)
Interest Expense / Debt = 8.60% (Interest Expense 75.2m / Debt 873.5m)
Taxrate = 1.32% (3.53m / 267.4m)
NOPAT = -374.0m (EBIT -379.0m * (1 - 1.32%)) [loss with tax shield]
Current Ratio = 1.91 (Total Current Assets 373.6m / Total Current Liabilities 195.4m)
Debt / Equity = -1.58 (negative equity) (Debt 873.5m / totalStockholderEquity, last quarter -553.8m)
Debt / EBITDA = -1.70 (negative EBITDA) (Net Debt 634.2m / EBITDA -373.2m)
Debt / FCF = 2.16 (Net Debt 634.2m / FCF TTM 294.1m)
Total Stockholder Equity = -370.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -96.92% (Net Income -458.0m / Total Assets 465.1m)
RoE = 123.6% (negative equity) (Net Income TTM -458.0m / Total Stockholder Equity -370.6m)
RoCE = -87.78% (EBIT -379.0m / Capital Employed (Equity -370.6m + L.T.Debt 802.4m))
RoIC = -139.1% (out of range, set to none) (NOPAT -374.0m / Invested Capital 268.8m)
WACC = 8.03% (E(2.58b)/V(3.45b) * Re(7.87%) + D(873.5m)/V(3.45b) * Rd(8.60%) * (1-Tc(0.01)))
Discount Rate = 7.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.76 | Cagr: 8.55%
[DCF] Terminal Value 75.44% ; FCFF base≈294.1m ; Y1≈295.3m ; Y5≈312.8m
[DCF] Fair Price = 16.65 (EV 4.87b - Net Debt 634.2m = Equity 4.23b / Shares 254.2m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: 96.67 | Revenue CAGR: 48.16% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.24 | Chg30d=+0.00% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.10 | Chg30d=-21.23% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.56 | Chg30d=+18.20% | Revisions=+40% | GrowthEPS=-11.0% | GrowthRev=-23.3%
EPS next Year (2027-12-31): EPS=0.68 | Chg30d=-15.21% | Revisions=-17% | GrowthEPS=+20.3% | GrowthRev=+8.4%
[Analyst] Revisions Ratio: +0% (up=3, down=3)